Rapt Therapeutics (RAPT) Competitors $10.96 -0.36 (-3.18%) As of 03:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RAPT vs. GYRE, IMTX, PROK, MNMD, PHAT, AMLX, DAWN, TBPH, DNTH, and KALVShould you be buying Rapt Therapeutics stock or one of its competitors? The main competitors of Rapt Therapeutics include Gyre Therapeutics (GYRE), Immatics (IMTX), ProKidney (PROK), Mind Medicine (MindMed) (MNMD), Phathom Pharmaceuticals (PHAT), Amylyx Pharmaceuticals (AMLX), Day One Biopharmaceuticals (DAWN), Theravance Biopharma (TBPH), Dianthus Therapeutics (DNTH), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Rapt Therapeutics vs. Its Competitors Gyre Therapeutics Immatics ProKidney Mind Medicine (MindMed) Phathom Pharmaceuticals Amylyx Pharmaceuticals Day One Biopharmaceuticals Theravance Biopharma Dianthus Therapeutics KalVista Pharmaceuticals Gyre Therapeutics (NASDAQ:GYRE) and Rapt Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk. Which has stronger earnings & valuation, GYRE or RAPT? Gyre Therapeutics has higher revenue and earnings than Rapt Therapeutics. Rapt Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGyre Therapeutics$102.19M7.82$12.09M$0.01829.70Rapt Therapeutics$1.53M118.48-$129.87M-$14.17-0.77 Is GYRE or RAPT more profitable? Gyre Therapeutics has a net margin of 4.08% compared to Rapt Therapeutics' net margin of 0.00%. Gyre Therapeutics' return on equity of 7.67% beat Rapt Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Gyre Therapeutics4.08% 7.67% 6.19% Rapt Therapeutics N/A -67.92%-59.59% Which has more risk and volatility, GYRE or RAPT? Gyre Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Comparatively, Rapt Therapeutics has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500. Do analysts recommend GYRE or RAPT? Rapt Therapeutics has a consensus target price of $21.57, indicating a potential upside of 96.82%. Given Rapt Therapeutics' higher probable upside, analysts plainly believe Rapt Therapeutics is more favorable than Gyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Rapt Therapeutics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.57 Do institutionals and insiders believe in GYRE or RAPT? 24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Rapt Therapeutics shares are held by institutional investors. 10.0% of Gyre Therapeutics shares are held by insiders. Comparatively, 6.6% of Rapt Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to GYRE or RAPT? In the previous week, Gyre Therapeutics and Gyre Therapeutics both had 1 articles in the media. Rapt Therapeutics' average media sentiment score of 0.67 beat Gyre Therapeutics' score of 0.44 indicating that Rapt Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapt Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGyre Therapeutics beats Rapt Therapeutics on 10 of the 16 factors compared between the two stocks. Get Rapt Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RAPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RAPT vs. The Competition Export to ExcelMetricRapt TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$181.28M$3.06B$5.76B$9.75BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-0.7721.0030.8325.91Price / Sales118.48392.25469.77121.46Price / CashN/A43.2325.7828.79Price / Book0.959.739.466.03Net Income-$129.87M-$54.08M$3.27B$265.29M7 Day Performance-6.56%3.12%2.37%2.86%1 Month Performance-17.66%4.57%3.88%1.23%1 Year Performance-41.20%10.22%30.52%19.11% Rapt Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RAPTRapt Therapeutics4.5716 of 5 stars$10.96-3.2%$21.57+96.8%-39.3%$181.28M$1.53M-0.7780GYREGyre Therapeutics0.0294 of 5 stars$7.85-3.6%N/A-36.3%$756.03M$105.76M785.7940IMTXImmatics1.8838 of 5 stars$6.21-1.9%$14.67+136.2%-49.2%$754.83M$168.65M-9.55260PROKProKidney3.7118 of 5 stars$2.54+7.6%$6.25+146.1%+0.8%$743.46M$80K-4.463MNMDMind Medicine (MindMed)2.8061 of 5 stars$9.75+1.5%$24.71+153.5%+69.3%$741.88MN/A-6.3740Positive NewsPHATPhathom Pharmaceuticals2.5549 of 5 stars$10.10-1.4%$17.50+73.3%-13.9%$716.49M$55.25M-2.14110AMLXAmylyx Pharmaceuticals3.4089 of 5 stars$7.99-0.1%$11.75+47.1%+317.0%$712.47M$87.37M-3.20200DAWNDay One Biopharmaceuticals2.2524 of 5 stars$6.81+0.9%$25.33+272.0%-48.9%$697.55M$131.16M-7.1760TBPHTheravance Biopharma2.0912 of 5 stars$13.61+3.5%$21.33+56.7%+71.9%$685.40M$64.38M56.71110High Trading VolumeDNTHDianthus Therapeutics1.161 of 5 stars$20.96+1.1%$53.00+152.9%-14.1%$674.70M$6.24M-6.4580News CoverageAnalyst RevisionHigh Trading VolumeKALVKalVista Pharmaceuticals4.0036 of 5 stars$13.34+3.6%$26.29+97.0%+6.2%$666.33MN/A-3.62100 Related Companies and Tools Related Companies Gyre Therapeutics Competitors Immatics Competitors ProKidney Competitors Mind Medicine (MindMed) Competitors Phathom Pharmaceuticals Competitors Amylyx Pharmaceuticals Competitors Day One Biopharmaceuticals Competitors Theravance Biopharma Competitors Dianthus Therapeutics Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RAPT) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rapt Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Rapt Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access